AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Cardiol Therapeutics Inc. (CRDL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.30

0.08 (6.56%)

At close: Feb 20, 2025, 3:59 PM

1.30

-0.38%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	1.24
Market Cap	106.49M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.38
PE Ratio (ttm)	-3.43
Forward PE	n/a
Analyst	Buy

Ask	1.35
Volume	341,192
Avg. Volume (20D)	324,908
Open	1.26
Previous Close	1.22
Day's Range	1.19 - 1.32
52-Week Range	1.15 - 3.12
Beta	undefined

About CRDL

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respirat...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Jan 15, 2019

Employees 22

Stock Exchange NASDAQ

Ticker Symbol CRDL

Website https://www.cardiolrx.com

Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for CRDL stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 589.66% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

4 months ago

-6.63%

Cardiol Therapeutics shares are trading lower afte... Unlock content with Pro Subscription

4 months ago

+3.7%

Cardiol Therapeutics shares are trading lower after the company announced a preliminary prospectus for a proposed public offering of common stock, size or amount not disclosed.

News

1 day ago · newsfilecorp.com

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failure Toronto, Ontario--(Newsfi...

2 weeks ago · newsfilecorp.com

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the researc...

3 weeks ago · zacks.com

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.

2 months ago · marketbeat.com

3 Penny Stocks Ready to Break Out in 2025

Known for their uncommonly pronounced risk/reward profile, penny stocks all too often entice investors with their low prices and potential for significant returns, only to fail to live up to those exp...